Invest in smarter healthcare

Lumos Diagnostics is a publicly-traded company listed on the Australian Securities Exchange (ASX:LDX).

World-Class Team

Point-of-care Products

Revenue-Generating Company

Global Commercial and Distribution Partnerships

Register for Lumos investor news and updates.

By entering your email address you are agreeing to our Privacy Policy.

Lumos Diagnostics Holdings Ltd

Key statistics for LDX

Market price
 $0.033
Market cap
 $-
Volume
 5,115,047
Day low
 $0.031
Day high
 $0.033
Change
 $0.000(0%)
16/09/2024 2:09 pm Change in substantial holder 193.7KB (2 pages)
16/09/2024 10:09 am Change in substantial holding 175.1KB (2 pages)
16/09/2024 9:09 am Lumos Appoints Thermo Fisher Scientific as US Distributor 189.2KB (2 pages)
13/09/2024 3:09 pm Change in substantial holding from RYD 181.3KB (3 pages)
12/09/2024 10:09 am Application for quotation of securities - LDX 20.7KB (8 pages)
11/09/2024 9:09 am Letter to Ineligible Shareholders 134.5KB (3 pages)
11/09/2024 9:09 am Letter to Eligible Shareholders 19.2MB (98 pages)
11/09/2024 9:09 am Retail Entitlement Offer Booklet 18.9MB (94 pages)
11/09/2024 9:09 am Retail Entitlement Offer Opens 237.7KB (2 pages)
06/09/2024 8:09 am Lumos Successfully Completes Institutional Entitlement Offer 261.3KB (3 pages)
04/09/2024 2:09 pm Becoming a substantial holder 210.3KB (2 pages)
04/09/2024 12:09 pm Ceasing to be a substantial holder 125.6KB (2 pages)
04/09/2024 10:09 am Proposed issue of securities - LDX 18.5KB (5 pages)
04/09/2024 10:09 am Proposed issue of securities - LDX 24.8KB (7 pages)
04/09/2024 10:09 am Entitlement Offer Cleansing Notice 232.0KB (3 pages)
04/09/2024 10:09 am Investor Presentation 18.1MB (53 pages)
04/09/2024 10:09 am Lumos Announces $10m Equity Raising and Welcomes Tenmile 332.8KB (6 pages)
04/09/2024 9:09 am Trading Halt 631.9KB (2 pages)
03/09/2024 4:09 pm Lumos Announces Intention to Undertake Entitlement Offer 334.9KB (3 pages)
27/08/2024 9:08 am Appendix 4G and Corporate Governance Statement 808.1KB (27 pages)
27/08/2024 9:08 am FY24 Full Year Results Announcement 287.8KB (5 pages)
27/08/2024 9:08 am FY24 Annual Report 3.4MB (77 pages)
27/08/2024 9:08 am FY24 Appendix 4E 201.7KB (2 pages)
26/08/2024 8:08 am Lumos and BDI Progress New Point of Care Test 329.7KB (3 pages)
05/08/2024 10:08 am Lumos Receives Research & Development Tax Rebate 286.5KB (2 pages)
01/08/2024 10:08 am Q4 FY24 Investor Presentation 1.3MB (20 pages)
31/07/2024 8:07 am Quarterly Activities/Appendix 4C Cash Flow Report 612.1KB (12 pages)
29/07/2024 2:07 pm Q4 FY24 Results Investor Briefing Invitation 282.4KB (2 pages)
11/07/2024 8:07 am Notification of cessation of securities - LDX 19.3KB (6 pages)
09/07/2024 8:07 am Lumos Expands Henry Schein FebriDx Distribution Partnership 273.1KB (3 pages)
04/07/2024 8:07 am Lumos Expands Distribution for FebriDx in AUS and NZ 425.6KB (3 pages)
19/06/2024 9:06 am Lumos Receives US$400k Phase 1 Milestone from Hologic 283.0KB (2 pages)
13/06/2024 9:06 am Change of Director's Interest Notice - CR 311.5KB (2 pages)
13/06/2024 9:06 am Change of Director's Interest Notice - SL 317.7KB (2 pages)
04/06/2024 9:06 am Lumos Receives Second US$5 million Hologic IP Payment 245.3KB (3 pages)
28/05/2024 11:05 am March 2024 Appendix 4C - Correction 564.5KB (7 pages)
06/05/2024 8:05 am Lumos Achieves Key Phase 1 Milestone in Hologic Agreement 309.0KB (3 pages)
02/05/2024 2:05 pm Lumos quarterly update video interview with CEO, Doug Ward 221.5KB (2 pages)
01/05/2024 12:05 pm Notification regarding unquoted securities - LDX 21.3KB (8 pages)
23/04/2024 9:04 am Quarterly Activities/Appendix 4C Cash Flow Report 560.2KB (11 pages)
08/04/2024 9:04 am Lumos announces positive FebriDx paediatric study results 374.9KB (4 pages)
02/04/2024 5:04 pm Change in substantial holding 154.1KB (2 pages)
02/04/2024 3:04 pm Application for quotation of securities - LDX 21.1KB (8 pages)
02/04/2024 3:04 pm Section 708A Cleansing Statement 191.8KB (2 pages)
29/02/2024 5:02 pm Change in substantial holding 229.5KB (2 pages)
28/02/2024 8:02 am Half Year Results Investor Presentation 3.8MB (32 pages)
28/02/2024 8:02 am Appendix 4D and Half Year Report 1.4MB (28 pages)
23/02/2024 11:02 am 1H FY24 Results Investor Briefing Invitation 252.9KB (2 pages)
14/02/2024 4:02 pm Change in substantial holding 177.2KB (2 pages)
12/02/2024 9:02 am Lumos Appoints Henry Schein as US Distributor for FebriDx 284.8KB (2 pages)
05/02/2024 9:02 am Lumos Investor Roadshow Presentation 1.5MB (25 pages)
31/01/2024 9:01 am Investor Information Sessions 286.7KB (2 pages)
31/01/2024 9:01 am Quarterly Activities/Appendix 4C Cash Flow Report 599.4KB (12 pages)
19/01/2024 2:01 pm Proposed issue of securities - LDX 30.2KB (6 pages)
19/01/2024 2:01 pm Notification regarding unquoted securities - LDX 34.1KB (9 pages)
17/01/2024 12:01 pm Change in substantial holding 166.3KB (2 pages)
16/01/2024 10:01 am New Hologic Agreements Investor Briefing Presentation 524.2KB (8 pages)
16/01/2024 10:01 am Additional Information Regarding Agreements with Hologic 229.5KB (3 pages)
15/01/2024 2:01 pm Notification of cessation of securities - LDX 27.7KB (6 pages)
15/01/2024 2:01 pm Investor Briefing on new Hologic Agreements 258.3KB (2 pages)
11/01/2024 9:01 am Lumos Signs Major Development and IP Agreements with Hologic 236.3KB (3 pages)
07/12/2023 2:12 pm Change in substantial holding 240.8KB (2 pages)
06/12/2023 8:12 am Commercial Operations Update Webinar Presentation 19.9MB (12 pages)
04/12/2023 1:12 pm Commercial Update Webinar US Product Launch Activities 211.9KB (2 pages)
04/12/2023 8:12 am Lumos Diagnostics FY2023 Full Year Results Webinar 211.0KB (2 pages)
14/11/2023 2:11 pm Becoming a substantial holder from RYD 171.6KB (2 pages)
03/11/2023 3:11 pm Change in substantial holding 216.9KB (2 pages)
03/11/2023 11:11 am Section 708A Cleansing Statement 293.6KB (2 pages)

"Lumos represents a compelling investment opportunity. We have secured strategic partnerships with leading healthcare companies. We are expanding our commercial services division across human health, animal health, food testing and molecular testing. We have secured key FDA clearances for our Point-of-care products. Collectively, our Company has firm foundations for considerable revenue growth."

Doug Ward | Lumos CEO and MD

Innovation at the point-of-care

2024 Lumos Diagnostics

Quick links
Engage with us